| 2. |
- Paquette, J A, et al.
(författare)
-
D/H in the refractory organics of comet 67P/Churyumov-Gerasimenko measured by Rosetta/COSIMA
- 2021
-
Ingår i: monthly notices of the royal astronomical society. ; 504:4
-
Tidskriftsartikel (refereegranskat)abstract
- The D/H ratio is a clue to the origin and evolution of hydrogen-bearing chemical species in Solar system materials. D/H has been observed in the coma of many comets, but most such measurements have been for gaseous water. We present the first in situ measurements of the D/H ratios in the organic refractory component of cometary dust particles collected at very low impact speeds in the coma of comet 67P/Churyumov-Gerasimenko (hereafter 67P) by the COSIMA instrument onboard Rosetta. The values measured by COSIMA are spatial averages over an approximately 35 × 50 µm2 area. The average D/H ratio for the 25 measured particles is (1.57 ± 0.54) × 10−3, about an order of magnitude higher than the Vienna Standard Mean Ocean Water (VSMOW), but more than an order of magnitude lower than the values measured in gas-phase organics in solar-like protostellar regions and hot cores. This relatively high averaged value suggests that refractory carbonaceous matter in comet 67P is less processed than the most primitive insoluble organic matter (IOM) in meteorites, which has a D/H ratio in the range of about 1 to 7 × 10−4. The cometary particles measured in situ also have a higher H/C ratio than the IOM. We deduce that the measured D/H in cometary refractory organics is an inheritance from the presolar molecular cloud from which the Solar system formed. The high D/H ratios observed in the cometary particles challenges models in which high D/H ratios result solely from processes that operated in the protosolar disc.
|
|
| 3. |
- Price, RB, et al.
(författare)
-
International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
- 2022
-
Ingår i: Molecular psychiatry. - : Springer Science and Business Media LLC. - 1476-5578 .- 1359-4184. ; 27:1112, s. 5096-5112
-
Tidskriftsartikel (refereegranskat)abstract
- Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar depression; post-traumatic stress disorder), included one or more control arms, did not provide any other study-administered treatment in conjunction with ketamine (although clinically prescribed concurrent treatments were allowable), and assessed outcome using either the Montgomery-Åsberg Depression Rating Scale or the Hamilton Rating Scale for Depression (HRSD-17). Individual patient-level data for at least one outcome was obtained from 17 of 25 eligible trials [pooled n = 809]. Rates of participant-level data availability across 33 moderators that were solicited from these 17 studies ranged from 10.8% to 100% (median = 55.6%). After data harmonization, moderators available in at least 40% of the dataset were tested sequentially, as well as with a data-driven, combined moderator approach. Robust main effects of ketamine on acute [~24-hours; β*(95% CI) = 0.58 (0.44, 0.72); p < 0.0001] and post-acute [~7 days; β*(95% CI) = 0.38 (0.23, 0.54); p < 0.0001] depression severity were observed. Two study-level moderators emerged as significant: ketamine effects (relative to placebo) were larger in studies that required a higher degree of previous treatment resistance to federal regulatory agency-approved antidepressant medications (≥2 failed trials) for study entry; and in studies that used a crossover design. A comprehensive data-driven search for combined moderators identified statistically significant, but modest and clinically uninformative, effects (effect size r ≤ 0.29, a small-medium effect). Ketamine robustly reduces depressive symptoms in a heterogeneous range of patients, with benefit relative to placebo even greater in patients more resistant to prior medications. In this largest effort to date to apply precision medicine approaches to ketamine treatment, no clinical or demographic patient-level features were detected that could be used to guide ketamine treatment decisions.Review Registration: PROSPERO Identifier: CRD42021235630
|
|
